The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Humanigen, Inc. (NASDAQ: HGEN) securities between May 16, 2020 and July 12, 2022.
According to the Humanigen lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) Humanigen’s lead product candidate, lenzilumab, posed risks to patients in addition to those disclosed by defendants; (ii) lenzilumab was not the only immunomodulator currently in late-stage clinical trials; (iii) lenzilumab was less effective in treating hospitalized COVID-19 patients than defendants had represented; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the lenzilumab Emergency Use Authorization and the ACTIV-5/BET-B study was unlikely to meet its primary endpoint; (v) accordingly, lenzilumab’s clinical and commercial prospects were overstated; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Humanigen you have until October 25, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
To receive more information, please fill out the form.